Tumor tissues exhibited typical metabolic reprogramming, characterized by the upregulation of low-density lipoprotein receptor (LDLR) expression and downregulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and 25-hydroxycholesterol 7-alpha-hydroxylase, despite lower serum LDL-C levels in patients with high-risk PTC and ATC. The gene discussed is LDLR; the disease is neoplasm.